Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.17849 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Samer Gawrieh und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, HIV Infections, Metabolic Diseases. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAAA NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Background
Metabolic dysfunction‐associated steatotic liver disease (MASLD) has recently been proposed as a replacement term for NAFLD.
Aims
To assess the effects of this new nomenclature on the prevalence and distribution of different SLD categories in people with HIV (PWH) and identified factors associated with MASLD and clinically significant fibrosis (CSF).
Methods
PWH were prospectively enrolled from 9 US centres and underwent clinical evaluation and vibration‐controlled transient elastography for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM). SLD was defined as CAP ≥ 263 dB/m, CSF as LSM of ≥8 kPa, and advanced fibrosis (AF) as LSM ≥ 12 kPa. The prevalence of SLD, MASLD, metabolic dysfunction and alcohol‐associated liver disease (MetALD), ALD, cryptogenic (cSLD), CSF and AF were determined. Uni‐ and multivariate logistic regression models were used to assess factors associated with MASLD and CSF risk.
Results
Of 1065 participants, 74% were male, mean (SD) age 51.6 ± 11.9 years, 46% non‐Hispanic Black and 74% with undetectable HIV RNA. The prevalence of SLD was 52%, MASLD 39%, MetALD 10%, ALD 3%, CSF 15% and AF 4%. Only 0.6% had cSLD. Black race was protective whereas obesity, ALT and AST levels were associated with increased risk of MASLD and CSF in MASLD. HIV or antiretroviral therapy did not affect MASLD risk.
Conclusions
MASLD and MetALD are the dominant causes of SLD in PWH, affecting almost half. Application of the new nomenclature resulted in minimal change in the proportion of patients with MASLD who would have been diagnosed previously with NAFLD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Division of Division of Gastroenterology and Hepatology, John Hopkins University, Baltimore, Maryland, USA.
- Division of Infectious Diseases, Department of Medicine, UTHealth, Houston, Texas, USA.
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
- Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA.
- Division of Infectious Diseases, Duke University School of Medicine, Durham, North Carolina, USA.
ORCID-Profile: Samer Gawrieh, Eduardo Vilar-Gomez, Jennifer C Price, Mark S Sulkowski, Naga Chalasani, Rohit Loomba
Förderung
- NIDDK NIH HHS
- NIAAA NIH HHS
- NHLBI NIH HHS
- NIDA NIH HHS
- NIH HHS
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Gawrieh, S., Vilar-Gomez, E., Woreta, T. A., Lake, J. E., Wilson, L. A., Price, J. C., Naggie, S., Sterling, R. K., Heath, S., Corey, K. E., Cachay, E. R., Ajmera, V., Tonascia, J., Sulkowski, M. S., Chalasani, N., & Loomba, R. (2024). Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17849
Vancouver
Gawrieh S, Vilar-Gomez E, Woreta TA, Lake JE, Wilson LA, Price JC, et al. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.17849
BibTeX
@article{Gawrieh2024,
author = {Gawrieh, Samer and Vilar-Gomez, Eduardo and Woreta, Tinsay A and Lake, Jordan E and Wilson, Laura A and Price, Jennifer C and Naggie, Susanna and Sterling, Richard K and Heath, Sonya and Corey, Kathleen E and Cachay, Edward R and Ajmera, Veeral and Tonascia, James and Sulkowski, Mark S and Chalasani, Naga and Loomba, Rohit},
title = {Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.17849}
}
EUVIMED